Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Pinto

Interventional Cardiology Kildeer, IL Medical Doctor

NPI 1992714034 CMS profile 135302

21481 N. Rand Rd., Kildeer, IL 60047

Open in the dashboard

General payments

$87,337

542 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Pinto of Kildeer, IL is reported in the CMS Open Payments database as having received $87,337 across 542 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,379 40
2024 General $9,950 83
2023 General $21,052 78
2022 General $13,891 106
2021 General $14,679 120
2020 General $8,753 51
2019 General $16,633 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Pinto
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jack Pinto were reported at $2,379. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jack Pinto Interventional Cardiology median Middle half National median
2019 $16,633 $1,097 $329–$3,048 $163
2020 $8,753 $473 $161–$1,480 $114
2021 $14,679 $677 $233–$1,827 $132
2022 $13,891 $978 $333–$2,724 $149
2023 $21,052 $1,136 $382–$2,986 $160
2024 $9,950 $1,181 $395–$3,326 $164
2025 $2,379 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $76,541 90 payments
  2. Medtronic, Inc. $1,645 15 payments
  3. Novartis Pharmaceuticals Corporation $935 56 payments
  4. E.R. Squibb & Sons, L.L.C. $914 63 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $723 54 payments
  6. Amarin Pharma Inc. $641 44 payments
  7. Janssen Pharmaceuticals, Inc $634 27 payments
  8. Amgen Inc. $450 28 payments
  9. Abiomed $355 11 payments
  10. Novo Nordisk Inc $349 15 payments
  11. Other $4,151 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $71,750 26 payments
  2. Food and Beverage $12,773 496 payments
  3. Travel and Lodging $2,228 15 payments
  4. Consulting Fee $375 1 payment
  5. Education $211 4 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $39,898 27 payments
  2. WATCHMAN Structural Heart $23,544 29 payments
  3. WATCHMAN Structural Heart $6,230 6 payments
  4. WATCHMAN Pain Management $5,481 10 payments
  5. SYMPLICITY G3 $1,508 13 payments
  6. General Therapies $808 8 payments
  7. XARELTO $634 27 payments
  8. ELIQUIS $584 44 payments
  9. Vascepa $569 41 payments
  10. JARDIANCE $491 35 payments
  11. Other $8,001 334 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

7,337

Median for Interventional Cardiology: 2,236

Drug cost

$1,559,979

Median for Interventional Cardiology: $380,412

Branded share of claims

24.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 410 $528,383
Entresto Sacubitril/Valsartan Brand 208 $335,409
Jardiance Empagliflozin Brand 169 $236,655
Repatha Sureclick Evolocumab Brand 140 $168,785
Xarelto Rivaroxaban Brand 76 $112,223
Repatha Syringe Evolocumab Brand 25 $28,239
Praluent Pen Alirocumab Brand 36 $26,283
Vascepa Icosapent Ethyl Brand 22 $20,526
Ezetimibe Generic 515 $13,763
Metoprolol Succinate Generic 721 $13,156

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$435,384

Of which drugs: $1,630

Medicare patients

957

Average age 77

Services billed

5,634

450 women, 507 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 52%
Atrial fibrillation 38%
Heart failure 35%
Diabetes 32%
Chronic kidney disease 31%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 80 320 $1,569
Infusion, normal saline solution, 250 cc J7050 Office 118 118 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
$138 410 —
JARDIANCE
$136 169 —
CAMZYOS
$109 — —
Repatha
$95 165 —
LEQVIO
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

542 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record